Jay , you can't say we re rate with the financials as we haven't a clue what they will contain. They might be good , bad or indifferent. If they are the last two we will most definitely be in for a rough ride I'm afraid. ATB
Regarding income, it's just a matter of waiting probably 3 or 4 weeks for a good read. Ebbers deal payments upto, so no clear idea of payments there atm. No point in talking about the Chinese monies. VistaGen . Who knows.
So let's see if we are in a good financial position as stated previously by the board.
Random It's nothing to do with when we got the last rns. It could have been yesterday for all I care. It's what's in the rns , and so far there has been one negative one after the other and a load of waffle. Many have been scrambling to find something, anything, positive to say. It's all if's, but's and maybes this past year . All the hot air about news tomorrow, news next week. Translating "over the coming months" to mean within the next couple of weeks. Financials need to hit soon, and be very good. Anything weak or negative in them and we will be a penny share. One must ask , who would buy NFX shares atm when they are always cheaper tomorrow.
I would like to thank Soup for his level headed factual posts these past months
You could be right Hale. I really don't know but was just a thought. It's just that the Everinsight deal was announced after the Nfx announcement. So as it proceeded the Everinsight deal I thought it might be included. ATB
We have customary clinical supply agreements and customary agreements with clinical research organizations to help us manage our nonclinical and clinical development programs. Each of our commercial agreements is non-exclusive, and we have no material contractual obligations under such agreements, except to the extent we order supplies or request services to be performed under work orders that we generate from time to time.
Material License Agreements Under this heading they list two agreements, included in which is their agreement made with Everinsight, which was announced after the collaboration agreement with Nuformix. The only reason I can see for this is their agreement with Nuformix is loose and any payments unspecified. If there was any form of regular payments to us it would have to have been disclosed in VistaGen's very long and detailed annual report.
The numbers at the top of the screen tell us what we are worth, no matter how much people think we should be worth. I am now in the red here, but believe that seeing we have had nothing but hot air and one poor rns after another for nine months, the price at the top of the page is exactly what we are worth. If the financials are good, plenty of cash in the bank, and we are told strong positive news of substance then I believe we will take off imo. Fingers crossed
Well, Chris Blackwell needs to deliver. The deals are there to be closed, and at least we know Chris has a proven track record. Let's all hope that they close Kissei , 004. We know Dan got in part of the tests, so full results must be July. Japan I guess now September summer holidays. Guess all depends on how quickly they want/will meet .. Exciting times while at todays lowly sp.
Interprete her words as you wish , but when she says there is nothing new to announce and looking forward they will rns the financials in July, I take to mean exactly that. And your final paragraph mentioning lack of information regarding detail on collaboration agreements rather sums up how little we are told as shareholders imo. ATB
Nervous times. Sp looking rather fragile atm, and can see, after Fleurs words, that there will be an absence of anything substantial before financials. Would expect then to hear in detail the commercial implications regarding the tie up with VistaGen. Starting to get rather tedious second guessing it's current state. ATB
On June 24, 2020, VistaGen Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “License Agreement”) with EverInsight Therapeutics Inc., a company incorporated under the laws of the British Virgin Islands (“EverInsight”), pursuant to which the Company granted EverInsight an exclusive license to develop and commercialize PH94B, the Company’s novel, rapid-onset neurosteroid drug candidate for multiple anxiety-related disorders, in Greater China (which includes Mainland China, Hong Kong, Macau and Taiwan), South Korea and Southeast Asia (which includes Indonesia, Malaysia, Philippines, Thailand and Vietnam) (collectively, the “Territory”). The Company retains development and commercialization rights for PH94B in the rest of the world.
Under the terms of the License Agreement, the Company is entitled to receive an upfront payment of $5.0 million. The Company may also receive up to an additional $172 million in milestone payments upon EverInsight’s achievement of certain developmental, regulatory and sales milestone events related to PH94B. The Company is also entitled to receive certain royalties on net sales, if any, of PH94B in the Territory following receipt of any required regulatory approval. In addition, EverInsight has the right to sublicense to affiliates and third parties in the Territory."